189 related articles for article (PubMed ID: 34280172)
1. Targeting SUMOylation in cancer.
Du L; Liu W; Rosen ST
Curr Opin Oncol; 2021 Sep; 33(5):520-525. PubMed ID: 34280172
[TBL] [Abstract][Full Text] [Related]
2. Small-Molecule Inhibitors Targeting Protein SUMOylation as Novel Anticancer Compounds.
Yang Y; Xia Z; Wang X; Zhao X; Sheng Z; Ye Y; He G; Zhou L; Zhu H; Xu N; Liang S
Mol Pharmacol; 2018 Aug; 94(2):885-894. PubMed ID: 29784649
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Potential of Targeting the SUMO Pathway in Cancer.
Kukkula A; Ojala VK; Mendez LM; Sistonen L; Elenius K; Sundvall M
Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503213
[TBL] [Abstract][Full Text] [Related]
4. TIF1γ protein regulates epithelial-mesenchymal transition by operating as a small ubiquitin-like modifier (SUMO) E3 ligase for the transcriptional regulator SnoN1.
Ikeuchi Y; Dadakhujaev S; Chandhoke AS; Huynh MA; Oldenborg A; Ikeuchi M; Deng L; Bennett EJ; Harper JW; Bonni A; Bonni S
J Biol Chem; 2014 Sep; 289(36):25067-78. PubMed ID: 25059663
[TBL] [Abstract][Full Text] [Related]
5. Targeting pancreatic cancer by TAK-981: a SUMOylation inhibitor that activates the immune system and blocks cancer cell cycle progression in a preclinical model.
Kumar S; Schoonderwoerd MJA; Kroonen JS; de Graaf IJ; Sluijter M; Ruano D; González-Prieto R; Verlaan-de Vries M; Rip J; Arens R; de Miranda NFCC; Hawinkels LJAC; van Hall T; Vertegaal ACO
Gut; 2022 Nov; 71(11):2266-2283. PubMed ID: 35074907
[TBL] [Abstract][Full Text] [Related]
6. SUMOylation of E2F1 Regulates Expression of EZH2.
Du L; Fakih MG; Rosen ST; Chen Y
Cancer Res; 2020 Oct; 80(19):4212-4223. PubMed ID: 32816857
[TBL] [Abstract][Full Text] [Related]
7. Ginkgoic acid impedes gastric cancer cell proliferation, migration and EMT through inhibiting the SUMOylation of IGF-1R.
Liu D; Li Z; Yang Z; Ma J; Mai S
Chem Biol Interact; 2021 Mar; 337():109394. PubMed ID: 33508304
[TBL] [Abstract][Full Text] [Related]
8. The ubiquitin ligase Smurf2 suppresses TGFβ-induced epithelial-mesenchymal transition in a sumoylation-regulated manner.
Chandhoke AS; Karve K; Dadakhujaev S; Netherton S; Deng L; Bonni S
Cell Death Differ; 2016 May; 23(5):876-88. PubMed ID: 26679521
[TBL] [Abstract][Full Text] [Related]
9. The Role of PIAS SUMO E3-Ligases in Cancer.
Rabellino A; Andreani C; Scaglioni PP
Cancer Res; 2017 Apr; 77(7):1542-1547. PubMed ID: 28330929
[TBL] [Abstract][Full Text] [Related]
10. Targeting SUMO Signaling to Wrestle Cancer.
Kroonen JS; Vertegaal ACO
Trends Cancer; 2021 Jun; 7(6):496-510. PubMed ID: 33353838
[TBL] [Abstract][Full Text] [Related]
11. Dynamic SUMOylation of MORC2 orchestrates chromatin remodelling and DNA repair in response to DNA damage and drives chemoresistance in breast cancer.
Zhang FL; Yang SY; Liao L; Zhang TM; Zhang YL; Hu SY; Deng L; Huang MY; Andriani L; Ma XY; Shao ZM; Li DQ
Theranostics; 2023; 13(3):973-990. PubMed ID: 36793866
[No Abstract] [Full Text] [Related]
12. Regulation of epithelial-mesenchymal transition through SUMOylation of transcription factors.
Bogachek MV; De Andrade JP; Weigel RJ
Cancer Res; 2015 Jan; 75(1):11-5. PubMed ID: 25524900
[TBL] [Abstract][Full Text] [Related]
13. Sumoylation of Flotillin-1 promotes EMT in metastatic prostate cancer by suppressing Snail degradation.
Jang D; Kwon H; Choi M; Lee J; Pak Y
Oncogene; 2019 Apr; 38(17):3248-3260. PubMed ID: 30631151
[TBL] [Abstract][Full Text] [Related]
14. A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models.
Lightcap ES; Yu P; Grossman S; Song K; Khattar M; Xega K; He X; Gavin JM; Imaichi H; Garnsey JJ; Koenig E; Zhang H; Lu Z; Shah P; Fu Y; Milhollen MA; Hatton BA; Riceberg J; Shinde V; Li C; Minissale J; Yang X; England D; Klinghoffer RA; Langston S; Galvin K; Shapiro G; Pulukuri SM; Fuchs SY; Huszar D
Sci Transl Med; 2021 Sep; 13(611):eaba7791. PubMed ID: 34524860
[TBL] [Abstract][Full Text] [Related]
15. The SUMO Pathway in Hematomalignancies and Their Response to Therapies.
Boulanger M; Paolillo R; Piechaczyk M; Bossis G
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31405039
[TBL] [Abstract][Full Text] [Related]
16. SUMO-Specific Cysteine Protease 1 Promotes Epithelial Mesenchymal Transition of Prostate Cancer Cells via Regulating SMAD4 deSUMOylation.
Zhang X; Wang H; Wang H; Xiao F; Seth P; Xu W; Jia Q; Wu C; Yang Y; Wang L
Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417919
[TBL] [Abstract][Full Text] [Related]
17. The post-translational modification, SUMOylation, and cancer (Review).
Han ZJ; Feng YH; Gu BH; Li YM; Chen H
Int J Oncol; 2018 Apr; 52(4):1081-1094. PubMed ID: 29484374
[TBL] [Abstract][Full Text] [Related]
18. A SUMOylation-dependent pathway regulates SIRT1 transcription and lung cancer metastasis.
Sun L; Li H; Chen J; Dehennaut V; Zhao Y; Yang Y; Iwasaki Y; Kahn-Perles B; Leprince D; Chen Q; Shen A; Xu Y
J Natl Cancer Inst; 2013 Jun; 105(12):887-98. PubMed ID: 23704280
[TBL] [Abstract][Full Text] [Related]
19. SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma.
Heynen GJJE; Baumgartner F; Heider M; Patra U; Holz M; Braune J; Kaiser M; Schäffer I; Bamopoulos SA; Ramberger E; Murgai A; Ng YLD; Demel UM; Laue D; Liebig S; Krüger J; Janz M; Nogai A; Schick M; Mertins P; Müller S; Bassermann F; Krönke J; Keller U; Wirth M
Blood Adv; 2023 Feb; 7(4):469-481. PubMed ID: 35917568
[TBL] [Abstract][Full Text] [Related]
20. SENP2 suppresses epithelial-mesenchymal transition of bladder cancer cells through deSUMOylation of TGF-βRI.
Tan M; Zhang D; Zhang E; Xu D; Liu Z; Qiu J; Fan Y; Shen B
Mol Carcinog; 2017 Oct; 56(10):2332-2341. PubMed ID: 28574613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
